We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Kinetics, Efficacy and Safety of C1-Esteraseremmer-N

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00119431
First Posted: July 13, 2005
Last Update Posted: May 4, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Sanquin
  Purpose

A multicentre study to investigate pharmacokinetics, clinical efficacy and safety of nanofiltered Cetor® (called C1-esteraseremmer-N during the development phase) for the treatment of hereditary angioedema (HAE) will be performed. This study KB2003.01 consists of three parts, part A pharmacokinetics (phase II), part B treatment of attacks of angioedema (phase III) and part C prophylactic use of C1 inhibitor (phase III). Part B + C will provide data on the efficacy of C1-esteraseremmer-N.

The changes in the manufacturing process of C1-esteraseremmer-N, compared to Cetor® (the currently marketed C1-inhibitor product), nanofiltration and omission of hepatitis B immunoglobulin, most likely will not affect tolerability. The nanofiltration will provide more safety regarding viruses.

In part A, the pharmacokinetics of C1-esteraseremmer-N in patients with hereditary angioedema will be compared with the current registered product, Cetor®, in a randomised, blinded cross-over design. This study has to provide evidence that changes in the manufacturing process have not affected pharmacokinetics. In addition, this study provides data on safety of C1-esteraseremmer-N.


Condition Intervention Phase
Hereditary Angioedema Type I Angioneurotic Edema Drug: C1 inhibitor concentrate Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema

Resource links provided by NLM:


Further study details as provided by Sanquin:

Primary Outcome Measures:
  • Pharmacokinetics of C1-esteraseremmer-N versus Cetor.

Secondary Outcome Measures:
  • Laboratory and clinical safety as well as clinical tolerance of C1-esteraseremmer-N versus current Cetor.

Estimated Enrollment: 12
Study Start Date: September 2005
Study Completion Date: March 2006
Detailed Description:

A multicentre study to investigate pharmacokinetics, clinical efficacy and safety of nanofiltered Cetor® (called C1-esteraseremmer-N during the development phase) for the treatment of hereditary angioedema (HAE) will be performed. This study KB2003.01 consists of three parts, part A pharmacokinetics (phase II), part B treatment of attacks of angioedema (phase III) and part C prophylactic use of C1 inhibitor (phase III). Part B + C will provide data on the efficacy of C1-esteraseremmer-N.

The changes in the manufacturing process of C1-esteraseremmer-N, compared to Cetor® (the currently marketed C1-inhibitor product), nanofiltration and omission of hepatitis B immunoglobulin, most likely will not affect tolerability. The nanofiltration will provide more safety regarding viruses.

In part A, the pharmacokinetics of C1-esteraseremmer-N in patients with hereditary angioedema will be compared with the current registered product, Cetor®, in a randomised, blinded cross-over design. This study has to provide evidence that changes in the manufacturing process have not affected pharmacokinetics. In addition, this study provides data on safety of C1-esteraseremmer-N. Twelve HAE patients without signs of an attack will receive an administration of 1,000 U, 1,500 U or 2,000 U of C1-esteraseremmer-N or Cetor® and later on the same dose of the other product. Both antigenic and functional C1 inhibitor levels will be determined. Laboratory safety parameters and adverse events will be monitored as well

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Established diagnosis of hereditary angioedema type I: i.e. markedly decreased C1 inhibitor activity, decreased level of C1 inhibitor antigen and a decreased level of C4.
  • Age ≥ 18 years
  • Body weight between 40 and 100 kg.
  • Signed Informed consent

Exclusion Criteria:

  • C1 inhibitor infusion within the last 7 days
  • Signs of any attack
  • Angioedema attack within 7 days before actual infusion of study medication
  • Change in the dosage of androgens in the last 14 days before the study
  • Change in oral anticonceptive medication in the last two months before the study
  • Pregnancy or lactation.
  • B-cell malignancy
  • Participation in another pharmaceutical clinical study, which can interfere with this study, in the last 3 months prior to the study
  • History of clinically relevant antibody development to C1 inhibitor
  • Use of oral anticoagulant medication in the last 14 days
  • Use of heparin within the last two days prior to the study
  • History of allergic reaction to C1 inhibitor concentrate or other blood products
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00119431


Locations
Netherlands
Academic Medical Centre
Amsterdam, Netherlands, 1100 DD
Erasmus Medical Centre
Rotterdam, Netherlands, 3015 GD
Sponsors and Collaborators
Sanquin
Investigators
Principal Investigator: M. M. Levi, Prof. Dr. Academic Medical Centre Amsterdam
  More Information

ClinicalTrials.gov Identifier: NCT00119431     History of Changes
Other Study ID Numbers: KB2003.01A
First Submitted: July 4, 2005
First Posted: July 13, 2005
Last Update Posted: May 4, 2009
Last Verified: May 2009

Keywords provided by Sanquin:
Hereditary angioedema type I (MeSH: angioneurotic edema, complement 1 inactivators)

Additional relevant MeSH terms:
Angioedema
Angioedemas, Hereditary
Hereditary Angioedema Types I and II
Vascular Diseases
Cardiovascular Diseases
Urticaria
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Genetic Diseases, Inborn
Complement C1 Inactivator Proteins
Complement Inactivating Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs


To Top